Breast Implants: Lymphoma and Blood Cancer
In a rush? You can use our Quick Contact Form to tell us the basic information about your case.
The Law Offices of Thomas J. Lamb represents people who have been harmed by unsafe medical products, or the families of those who have died.
We are currently investigating breast implant cases that involve lymphoma and blood cancers.
In more detail, the US Food and Drug Administration (FDA) has received reports about women who have had breast implant procedures done and, later, were diagnosed with these medical conditions:
- Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL)
- Anaplastic Large Cell Lymphoma (ALCL)
- Non-Hodgkin Lymphoma (also known as Non-Hodgkin’s Lymphoma, NHL, or just Lymphoma)
- T-cell Lymphoma
- Blood Cancer
We encourage you to submit a Breast Implants Cancer Case Review – it is free, confidential, and there is no obligation. Or, if you prefer, call our toll-free number, (800) 426-9535, to speak directly to attorney Tom Lamb about a possible breast implants case. Either way, you will get Mr. Lamb’s impressions — not an intake person, a paralegal, nor some other lawyer — about your case based on his many years of experience.
- Summary of Information
- The Disease
- FDA Information
- Frequently Asked Questions
➤ About the Disease
➤ Risk Factors
We are here to help the women and families who have experienced this unfortunate situation.
We have successfully handled personal injury and wrongful death cases for people throughout the country.
Our firm does not put its clients into large class actions lawsuits. Rather, an individual lawsuit is filed for each case.
There are no costs associated with having us review your possible breast implants case.
Be assured that the information you provide to our law firm is treated as strictly confidential.
Submitting a case evaluation does not obligate you to hire our law firm.
Lastly, we want you to know that you will get a reply directly from attorney Tom Lamb no later than the next business day.
Most Recent Article on This Topic
On October 18, 2017, the JAMA Surgery journal published an article titled “Breast Implant–Associated Anaplastic Large Cell Lymphoma A Systematic Review,” in which they discuss the rate of occurrence of the condition.
To read more of this article, click below:
As explained in my previous articles (listed at the bottom of this page), BIA-ALCL is a rare non-Hodgkin lymphoma of T-cell origin that is typically found in the effusion fluid (seroma) surrounding the breast implant, or contained within the fibrous scar capsule. Though this condition is not frequently diagnosed, the consequences can be fatal if left untreated.
According to the JAMA article, diagnoses of BIA-ALCL are increasing as doctors and patients learn more about the condition. While the condition is certainly rare, this new data suggests that it may not be as rare as it was initially thought to be:
The exact incidence is unknown due to the lack of standardized criteria for diagnosis; however, it is estimated to be 1 case per 30 000 women with implants per year, with a median time to onset after implantation of 10.7 years. A prospective study on Natrelle (Allergan) 410 breast implant risk factor analysis found that 4 patients of 17 656 who received breast implants developed BIA-ALCL, suggesting that the incidence may actually be closer to 1 case per 4000 [citations omitted].
However, many practitioners are still unaware of–or at least unfamiliar with–many important factors of BIA-ALCL. In order to address this lack of knowledge, more information on the risks, symptoms, development, diagnosis, and treatment of BIA-ALCL is being distributed to the appropriate healthcare providers as it is published.
The JAMA article closes with the following call to action for surgeons and patients:
Before breast augmentation or reconstruction, surgeons need to convey the risk of breast implant–associated anaplastic large cell lymphoma to patients, with particular emphasis on the established linkage to textured implants; patients must be educated on the importance of routine surveillance after implantation, and it is likely that increased follow-up will lead to a further rise in this diagnosis.
Given increased access to necessary information on BIA-ALCL, the hope is that doctors will be better equipped to diagnose and successfully treat women exhibiting symptoms of the condition.
We will continue to monitor the medical literature concerning breast implants and this rare type of lymphoma, and report on new information as it becomes available.
Written by: Heather Helmendach, Legal Assistant
Law Offices of Thomas J. Lamb, P.A.
Our earlier articles about this breast implants lymphoma cancer situation:
- What is the Risk of Death Due to Breast Implant-Associated Lymphoma?
- Treatments For Breast Implants Associated Lymphoma And Blood Cancer
- Breast Implants and Lymphoma: Who’s to Blame?
- Breast Implants Lymphoma Cancer: Diagnosis And Treatment Developments
- Breast Implant Lymphoma: Causes Uncertain, but Costs Undeniable
- March 2017 FDA Report: Breast Implants Linked To Lymphoma Blood Cancer
- Breast Implants Linked to Rare Lymphoma Blood Cancer